Holding on to Junk Bonds: Intron Retention in Cancer and Therapy
- 15 February 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (4) , 779-789
Abstract
Intron retention (IR) in cancer was for a long time overlooked by the scientific community, as it was previously considered to be an artifact of a dysfunctional spliceosome. Technological advancements made in the last decade offer unique opportunities to explore the role of IR as a widespread phenomenon that contributes to the transcriptional diversity of many cancers. Numerous studies in cancer have shed light on dysregulation of cellular mechanisms that lead to aberrant and pathologic IR. IR is not merely a mechanism of gene regulation, but rather it can mediate cancer pathogenesis and therapeutic resistance in various human diseases. The burden of IR in cancer is governed by perturbations to mechanisms known to regulate this phenomenon and include epigenetic variation, mutations within the gene body, and splicing factor dysregulation. This review summarizes possible causes for aberrant IR and discusses the role of IR in therapy or as a consequence of disease treatment. As neoepitopes originating from retained introns can be presented on the cancer cell surface, the development of personalized cancer vaccines based on IR-derived neoepitopes should be considered. Ultimately, a deeper comprehension about the origins and consequences of aberrant IR may aid in the development of such personalized cancer vaccines.Keywords
All Related Versions
Funding Information
- National Health and Medical Research Council (1177305)
- National Health and Medical Research Council (#1080530, #1061906, #1128175, #1129901)
- Cancer Council NSW (RG11-12, RG14-09, RG20-12)
This publication has 102 references indexed in Scilit:
- Cancer Epigenetics: New Therapies and New ChallengesJournal of Drug Delivery, 2013
- Tuning of Alternative Splicing - Switch From Proto-Oncogene to Tumor SuppressorInternational Journal of Biological Sciences, 2013
- The Evolutionary Landscape of Alternative Splicing in Vertebrate SpeciesScience, 2012
- Evolutionary Dynamics of Gene and Isoform Regulation in Mammalian TissuesScience, 2012
- Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndromeNature Genetics, 2011
- Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translationProceedings of the National Academy of Sciences, 2011
- Identification of ASF/SF2 as a Critical, Allele-Specific Effector of the Cyclin D1b OncogeneCancer Research, 2010
- Expansion of the eukaryotic proteome by alternative splicingNature, 2010
- Proteases in MHC Class I Presentation and Cross-PresentationThe Journal of Immunology, 2009
- Alternative isoform regulation in human tissue transcriptomesNature, 2008